PubRank

Jeffrey A Engelman

Author PubWeight™ 322.38‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010 36.78
2 Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011 16.94
3 Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012 15.91
4 Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008 14.47
5 Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014 9.94
6 ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012 9.76
7 First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008 9.43
8 EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008 9.29
9 Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012 8.64
10 Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med 2012 8.41
11 Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010 7.78
12 The PI3K pathway as drug target in human cancer. J Clin Oncol 2010 6.83
13 Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011 6.69
14 Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med 2010 6.38
15 Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2009 5.70
16 Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 2005 5.07
17 Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 2007 5.01
18 Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 2008 4.95
19 Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell 2007 4.85
20 EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2012 4.72
21 Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med 2011 4.51
22 Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst 2005 4.19
23 Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A 2009 4.02
24 Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A 2011 3.97
25 Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med 2013 3.42
26 Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell 2010 3.40
27 Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell 2012 3.39
28 Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev 2009 3.35
29 BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov 2011 3.34
30 BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal 2010 3.25
31 A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 2012 3.24
32 PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol 2009 3.24
33 Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol 2010 3.15
34 Phosphoinositide 3-kinase catalytic subunit deletion and regulatory subunit deletion have opposite effects on insulin sensitivity in mice. Mol Cell Biol 2005 3.09
35 Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A 2012 2.89
36 Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 2005 2.88
37 ALK in lung cancer: past, present, and future. J Clin Oncol 2013 2.70
38 ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res 2013 2.65
39 EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med 2011 2.46
40 STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res 2011 2.35
41 Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Res 2005 2.24
42 Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J Clin Invest 2011 2.20
43 An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res 2010 2.14
44 The p85 regulatory subunit of phosphoinositide 3-kinase down-regulates IRS-1 signaling via the formation of a sequestration complex. J Cell Biol 2005 2.04
45 mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer. Sci Transl Med 2013 1.98
46 Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer. Sci Signal 2013 1.96
47 MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res 2012 1.87
48 Tyrosine kinase gene rearrangements in epithelial malignancies. Nat Rev Cancer 2013 1.80
49 Modeling oncogene addiction using RNA interference. Proc Natl Acad Sci U S A 2008 1.79
50 EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro Oncol 2010 1.73
51 A combinatorial strategy for treating KRAS-mutant lung cancer. Nature 2016 1.69
52 Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Res 2011 1.67
53 TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Sci Transl Med 2013 1.67
54 Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res 2011 1.66
55 Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer. J Clin Oncol 2011 1.63
56 Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov 2011 1.57
57 PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1. Proc Natl Acad Sci U S A 2013 1.57
58 Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers. Oncotarget 2011 1.55
59 Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. Cancer Res 2013 1.52
60 SnapShot: non-small cell lung cancer. Cancer Cell 2012 1.47
61 Activation of PI3K signaling in Merkel cell carcinoma. Clin Cancer Res 2012 1.45
62 FGFR1 amplification in squamous cell carcinoma of the lung. J Thorac Oncol 2012 1.43
63 Characteristics of lung cancers harboring NRAS mutations. Clin Cancer Res 2013 1.41
64 Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists. Cell Cycle 2009 1.29
65 Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014 1.28
66 Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. Cancer Discov 2013 1.27
67 Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET. Cancer Res 2012 1.27
68 Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discov 2014 1.26
69 Genetic changes in squamous cell lung cancer: a review. J Thorac Oncol 2012 1.23
70 Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer. Clin Cancer Res 2013 1.21
71 mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. Cancer Discov 2013 1.21
72 Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human cancer. Cancer Res 2010 1.20
73 Apoptosis in targeted therapy responses: the role of BIM. Adv Pharmacol 2012 1.17
74 Biochemistry. PI3K charges ahead. Science 2007 1.11
75 Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer. Oncologist 2011 1.10
76 Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases. Proc Natl Acad Sci U S A 2012 1.09
77 Toward noninvasive genomic screening of lung cancer patients. J Clin Oncol 2009 1.07
78 AACR Cancer Progress Report 2014. Clin Cancer Res 2014 1.05
79 Differences underlying EGFR and HER2 oncogene addiction. Cell Cycle 2010 1.02
80 Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancer. Cancer Res 2011 0.98
81 Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2. Clin Cancer Res 2013 0.97
82 Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med 2013 0.92
83 PIKing the right patient. Clin Cancer Res 2010 0.86
84 Not just gRASping at flaws: finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers. Cancer Sci 2014 0.82
85 Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors. J Thorac Oncol 2014 0.79
86 A new BATTLE in the evolving war on cancer. Cancer Discov 2011 0.77
87 Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy. J Thorac Oncol 2008 0.76
88 Case records of the Massachusetts General Hospital. Case 19-2010. A 35-year-old man with adenocarcinoma of the cecum. N Engl J Med 2010 0.75
89 [(18)F]-FLT PET to predict early response to neoadjuvant therapy in KRAS wild-type rectal cancer: a pilot study. Ann Nucl Med 2015 0.75
90 Crizotinib Resensitization by Compound Mutation. N Engl J Med 2016 0.75
91 Correction: KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer. Elife 2017 0.75